The SFV-aPDL1 induced >40% complete regressions and was superior to AAV-aPDL1 treatment, as well as to monotherapy with anti-PDL1 given systemically or locally in a murine MC38 tumour model. This evidence concerns the gene CD274 and neoplasm.